BRPI0923231A2 - anticorpo anti-cmet. - Google Patents

anticorpo anti-cmet.

Info

Publication number: BRPI0923231A2
Authority: BR; Brazil
Prior art keywords: cmet antibody; cmet; antibody
Prior art date: 2008-12-02

Application number

BRPI0923231A

Other languages

English (en)

Inventor

Cédric Bes

Liliane Goetsch

Thierry Wurch

Original Assignee

Pf Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-02

Filing date

2009-12-02

Publication date

2016-01-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41693124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0923231(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-12-02 Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/en

2009-12-02 Application filed by Pf Medicament filed Critical Pf Medicament

2009-12-02 Priority to BR122019023930-4A priority Critical patent/BR122019023930B1/pt

2016-01-26 Publication of BRPI0923231A2 publication Critical patent/BRPI0923231A2/pt

2020-04-28 Publication of BRPI0923231B1 publication Critical patent/BRPI0923231B1/pt

2021-05-25 Publication of BRPI0923231B8 publication Critical patent/BRPI0923231B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Connection Of Motors, Electrical Generators, Mechanical Devices, And The Like (AREA)
Medicinal Preparation (AREA)

BRPI0923231A 2008-12-02 2009-12-02 anticorpo anti-cmet BRPI0923231B8 (pt)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
BR122019023930-4A BR122019023930B1 (pt)	2008-12-02	2009-12-02	Anticorpo anti-cmet, seu uso e processo de preparação, ácido nucleico isolado que o codifica, composição que o compreende, vetor, bem como método de diagnóstico in vitro de doença

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/IB2008/055663 WO2010064089A1 (en)	2008-12-02	2008-12-02	Novel anti-cmet antibody
US18450209P	2009-06-05	2009-06-05
PCT/EP2009/066201 WO2010069765A1 (en)	2008-12-02	2009-12-02	ANTI-cMET ANTIBODY

Publications (3)

Publication Number	Publication Date
BRPI0923231A2 true BRPI0923231A2 (pt)	2016-01-26
BRPI0923231B1 BRPI0923231B1 (pt)	2020-04-28
BRPI0923231B8 BRPI0923231B8 (pt)	2021-05-25

Family

ID=41693124

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BR122019023930-4A BR122019023930B1 (pt)	2008-12-02	2009-12-02	Anticorpo anti-cmet, seu uso e processo de preparação, ácido nucleico isolado que o codifica, composição que o compreende, vetor, bem como método de diagnóstico in vitro de doença
BRPI0923231A BRPI0923231B8 (pt)	2008-12-02	2009-12-02	anticorpo anti-cmet

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
BR122019023930-4A BR122019023930B1 (pt)	2008-12-02	2009-12-02	Anticorpo anti-cmet, seu uso e processo de preparação, ácido nucleico isolado que o codifica, composição que o compreende, vetor, bem como método de diagnóstico in vitro de doença

Country Status (38)

Country	Link
US (4)	US8741290B2 (pt)
EP (4)	EP3135691B1 (pt)
JP (3)	JP5863458B2 (pt)
KR (1)	KR101838299B1 (pt)
CN (2)	CN103351438B (pt)
AR (1)	AR074439A1 (pt)
AU (3)	AU2009328318C1 (pt)
BR (2)	BR122019023930B1 (pt)
CA (1)	CA2743433C (pt)
CL (2)	CL2011001296A1 (pt)
CO (1)	CO6382139A2 (pt)
CR (1)	CR20110324A (pt)
CY (2)	CY1119172T1 (pt)
DK (2)	DK2370468T3 (pt)
EC (1)	ECSP11011127A (pt)
ES (3)	ES2629855T3 (pt)
GE (2)	GEP20135930B (pt)
HR (2)	HRP20171011T8 (pt)
HU (3)	HUE051288T2 (pt)
IL (2)	IL213273A0 (pt)
LT (2)	LT2370468T (pt)
MA (1)	MA32892B1 (pt)
MX (2)	MX2011005677A (pt)
MY (2)	MY185200A (pt)
NZ (1)	NZ593853A (pt)
PE (1)	PE20120343A1 (pt)
PH (1)	PH12015501515A1 (pt)
PL (3)	PL2370468T3 (pt)
PT (3)	PT3431502T (pt)
RS (2)	RS58018B1 (pt)
RU (2)	RU2560257C2 (pt)
SA (2)	SA112331005B1 (pt)
SG (2)	SG171851A1 (pt)
SI (3)	SI3431502T1 (pt)
TN (1)	TN2011000216A1 (pt)
TW (2)	TWI459964B (pt)
WO (1)	WO2010069765A1 (pt)
ZA (1)	ZA201105164B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2014681A1 (en)	2007-07-12	2009-01-14	Pierre Fabre Medicament	Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) *	2008-12-02	2013-10-01	Pierre Fabre Medicament	Anti-c-Met antibody
EP2287197A1 (en) *	2009-08-21	2011-02-23	Pierre Fabre Medicament	Anti-cMET antibody and its use for the detection and the diagnosis of cancer
JP6055312B2 (ja)	2010-03-10	2017-01-11	ゲンマブエー／エス	Ｃ−ｍｅｔに対するモノクローナル抗体
US9150655B2 (en)	2010-09-03	2015-10-06	Academia Sinica	Anti-C-met antibody and methods of use thereof
EP2635602B1 (en)	2010-11-03	2016-09-07	Argen-X Nv	Anti c-met antibodies
CN107903325B (zh)	2011-05-16	2021-10-29	埃泰美德(香港)有限公司	多特异性fab融合蛋白及其使用方法
KR101865223B1 (ko)	2011-10-05	2018-06-08	삼성전자주식회사	항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130036993A (ko) *	2011-10-05	2013-04-15	삼성전자주식회사	ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
WO2013064700A2 (en)	2011-11-03	2013-05-10	Argen-X B.V.	Chimeric polypeptides and methods of use
KR101463098B1 (ko)	2011-11-28	2014-11-27	한국생명공학연구원	ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
US8900582B2 (en)	2011-12-22	2014-12-02	Samsung Electronics Co., Ltd.	Deimmunized anti c-Met humanized antibodies and uses thereof
US10377827B2 (en)	2012-06-21	2019-08-13	Sorrento Therapeutics, Inc.	Antigen binding proteins that bind c-met
EP2708556B1 (en)	2012-09-12	2018-11-07	Samsung Electronics Co., Ltd	Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
EP2839860B1 (en)	2012-10-12	2019-05-01	MedImmune Limited	Pyrrolobenzodiazepines and conjugates thereof
WO2014140174A1 (en)	2013-03-13	2014-09-18	Spirogen Sàrl	Pyrrolobenzodiazepines and conjugates thereof
KR102049990B1 (ko) *	2013-03-28	2019-12-03	삼성전자주식회사	c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
SG11201508875TA (en)	2013-04-30	2015-11-27	Agency Science Tech & Res	Mab 2 anti-met antibody
US9567641B2 (en) *	2013-07-03	2017-02-14	Samsung Electronics Co., Ltd.	Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en)	2013-11-15	2017-08-01	Samsung Electronics Co., Ltd.	Method of combination therapy using an anti-C-Met antibody
CA2949045C (en) *	2013-12-20	2022-07-05	Development Center For Biotechnology	Alpha-enolase specific antibodies and methods of uses in cancer therapy
EP3193940A1 (en)	2014-09-10	2017-07-26	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
WO2016149265A1 (en) *	2015-03-16	2016-09-22	Kolltan Pharmaceuticals, Inc.	Anti-met antibodies and methods of use thereof
JP6669882B2 (ja) *	2016-02-05	2020-03-18	ヘリックスミスカンパニーリミテッド	抗−ｃ−ＭＥＴ抗体及びその用途
AU2017233121B2 (en)	2016-03-15	2023-12-21	Itabmed (Hk) Limited	Multispecific Fab fusion proteins and use thereof
MX2018014175A (es)	2016-05-17	2020-02-07	Abbvie Biotherapeutics Inc	Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
US10457726B2 (en)	2016-06-30	2019-10-29	University Of Connecticut	Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
EP3525829A1 (en)	2016-10-11	2019-08-21	Medimmune Limited	Antibody-drug conjugates with immune-mediated therapy agents
RU2741228C2 (ru) *	2016-11-14	2021-01-22	Общество С Ограниченной Ответственностью "Панацела Лабс"	Противоопухолевые эффекты вирусного вектора, кодирующего толл-подобный рецептор и агонист толл-подобного рецептора
TWI782930B (zh)	2016-11-16	2022-11-11	美商再生元醫藥公司	抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US20180230218A1 (en) *	2017-01-04	2018-08-16	Immunogen, Inc.	Met antibodies and immunoconjugates and uses thereof
CN109771642B (zh)	2017-11-13	2022-09-20	同济大学苏州研究院	c-MET激动型抗体及其用途
GB201803892D0 (en) *	2018-03-12	2018-04-25	Ultrahuman Six Ltd	C-met binding agents
MX2020012418A (es)	2018-05-23	2021-04-28	Adc Therapeutics Sa	Adyuvante molecular.
MA53284A (fr) *	2018-08-08	2022-01-26	Dragonfly Therapeutics Inc	Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
CN112867735B (zh)	2018-09-07	2025-05-09	埃泰美德(香港)有限公司	双特异性抗原结合蛋白及其用途
CN109541221B (zh) *	2018-10-24	2022-03-22	益善生物技术股份有限公司	一种c-Met特异性抗体、组合物及试剂盒
KR102353568B1 (ko) *	2018-11-14	2022-01-20	주식회사 헬릭스미스	안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
CN113874392B (zh) *	2019-03-28	2025-10-21	丹尼斯科美国公司	工程化抗体
CN121015920A (zh)	2019-09-16	2025-11-28	瑞泽恩制药公司	用于免疫pet成像的放射性标记的met结合蛋白
JP7510518B2 (ja)	2020-09-01	2024-07-03	レメゲンシーオー．，エルティーディー．	抗ｃ－Ｍｅｔ抗体薬物複合体及びその応用
US20230372528A1 (en)	2020-10-16	2023-11-23	University Of Georgia Research Foundation, Inc.	Glycoconjugates
GB202102396D0 (en)	2021-02-19	2021-04-07	Adc Therapeutics Sa	Molecular adjuvant
WO2022216796A1 (en)	2021-04-06	2022-10-13	Abbvie Biotherapeutics Inc.	Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin
KR20230166099A (ko) *	2021-04-08	2023-12-06	비온디스 비.브이.	항-c-met 항체 및 항체-약물 접합체
AR125473A1 (es)	2021-04-29	2023-07-19	Abbvie Inc	Conjugados de anticuerpo anti-c-met y fármaco
KR20240095442A (ko)	2021-11-03	2024-06-25	항저우 디에이씨 바이오테크 씨오, 엘티디	항체의 특이적 접합
US20230285394A1 (en)	2022-03-11	2023-09-14	Abbvie Biotherapeutics Inc.	Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertinib
CN121240891A (zh)	2023-05-23	2025-12-30	艾伯维制造管理无限公司	使用抗c-met抗体药物缀合物的治疗方法
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4424200A (en)	1979-05-14	1984-01-03	Nuc Med Inc.	Method for radiolabeling proteins with technetium-99m
US4479930A (en)	1982-07-26	1984-10-30	Trustees Of The University Of Massachusetts	Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4831175A (en)	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8924581D0 (en)	1989-11-01	1989-12-20	Pa Consulting Services	Bleaching of hair
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
JPH05244982A (ja)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5686292A (en)	1995-06-02	1997-11-11	Genentech, Inc.	Hepatocyte growth factor receptor antagonist antibodies and uses thereof
SK9072003A3 (en) *	2001-01-09	2003-11-04	Merck Patent Gmbh	Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
EP1592713A2 (en) *	2003-02-13	2005-11-09	Pharmacia Corporation	Antibodies to c-met for the treatment of cancers
HN2004000285A (es)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
CN1922208A (zh) *	2003-12-11	2007-02-28	健泰科生物技术公司	用于抑制c－met二聚化及活化的方法和组合物
US7476724B2 (en) *	2004-08-05	2009-01-13	Genentech, Inc.	Humanized anti-cmet antibodies
JP5255435B2 (ja) *	2005-04-26	2013-08-07	メディミューン，エルエルシー	ヒンジドメイン操作による抗体エフェクター機能の調節
EP2397497A3 (en)	2005-07-18	2013-11-27	Amgen, Inc	Human anti-B7RP1 neutralizing antibodies
EP2311876A3 (en) *	2005-07-28	2011-04-27	Novartis AG	M-CSF-specific monoclonal antibody and uses thereof
AU2007245181A1 (en) *	2006-03-30	2007-11-08	Novartis Ag	Compositions and methods of use for antibodies of c-Met
EP2014681A1 (en)	2007-07-12	2009-01-14	Pierre Fabre Medicament	Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en)	2008-12-02	2013-10-01	Pierre Fabre Medicament	Anti-c-Met antibody

2009
- 2009-12-01 AR ARP090104624A patent/AR074439A1/es active IP Right Grant
- 2009-12-02 GE GEAP200912279A patent/GEP20135930B/en unknown
- 2009-12-02 BR BR122019023930-4A patent/BR122019023930B1/pt active IP Right Grant
- 2009-12-02 PE PE2011001117A patent/PE20120343A1/es active IP Right Grant
- 2009-12-02 LT LTEP09771324.2T patent/LT2370468T/lt unknown
- 2009-12-02 SG SG2011038817A patent/SG171851A1/en unknown
- 2009-12-02 PL PL09771324T patent/PL2370468T3/pl unknown
- 2009-12-02 MY MYPI2011002426A patent/MY185200A/en unknown
- 2009-12-02 CN CN201310286587.2A patent/CN103351438B/zh active Active
- 2009-12-02 MY MYPI2020006937A patent/MY192567A/en unknown
- 2009-12-02 MX MX2011005677A patent/MX2011005677A/es active IP Right Grant
- 2009-12-02 TW TW098141151A patent/TWI459964B/zh active
- 2009-12-02 ES ES09771324.2T patent/ES2629855T3/es active Active
- 2009-12-02 GE GEAP200912919A patent/GEP20146207B/en unknown
- 2009-12-02 EP EP16192250.5A patent/EP3135691B1/en active Active
- 2009-12-02 RS RS20181344A patent/RS58018B1/sr unknown
- 2009-12-02 ES ES18188726T patent/ES2827277T3/es active Active
- 2009-12-02 DK DK09771324.2T patent/DK2370468T3/en active
- 2009-12-02 SI SI200932092T patent/SI3431502T1/sl unknown
- 2009-12-02 PL PL18188726T patent/PL3431502T3/pl unknown
- 2009-12-02 SG SG2013005772A patent/SG187518A1/en unknown
- 2009-12-02 RU RU2011124751/10A patent/RU2560257C2/ru active
- 2009-12-02 JP JP2011539008A patent/JP5863458B2/ja active Active
- 2009-12-02 BR BRPI0923231A patent/BRPI0923231B8/pt active IP Right Grant
- 2009-12-02 DK DK16192250.5T patent/DK3135691T3/en active
- 2009-12-02 CA CA2743433A patent/CA2743433C/en active Active
- 2009-12-02 PL PL16192250T patent/PL3135691T3/pl unknown
- 2009-12-02 HU HUE18188726A patent/HUE051288T2/hu unknown
- 2009-12-02 PT PT181887266T patent/PT3431502T/pt unknown
- 2009-12-02 CN CN200980148150.4A patent/CN102227446B/zh active Active
- 2009-12-02 HU HUE09771324A patent/HUE035047T2/en unknown
- 2009-12-02 SI SI200931893T patent/SI3135691T1/sl unknown
- 2009-12-02 EP EP20187010.2A patent/EP3757132A1/en active Pending
- 2009-12-02 KR KR1020117013758A patent/KR101838299B1/ko active Active
- 2009-12-02 PT PT16192250T patent/PT3135691T/pt unknown
- 2009-12-02 EP EP18188726.6A patent/EP3431502B1/en active Active
- 2009-12-02 RS RS20170671A patent/RS56204B1/sr unknown
- 2009-12-02 WO PCT/EP2009/066201 patent/WO2010069765A1/en not_active Ceased
- 2009-12-02 HR HRP20171011TT patent/HRP20171011T8/hr unknown
- 2009-12-02 ES ES16192250T patent/ES2697098T3/es active Active
- 2009-12-02 US US13/132,211 patent/US8741290B2/en active Active
- 2009-12-02 HU HUE16192250A patent/HUE040553T2/hu unknown
- 2009-12-02 TW TW103130374A patent/TWI523866B/zh active
- 2009-12-02 EP EP09771324.2A patent/EP2370468B1/en active Active
- 2009-12-02 NZ NZ593853A patent/NZ593853A/xx unknown
- 2009-12-02 RU RU2015127471A patent/RU2015127471A/ru not_active Application Discontinuation
- 2009-12-02 PT PT97713242T patent/PT2370468T/pt unknown
- 2009-12-02 AU AU2009328318A patent/AU2009328318C1/en active Active
- 2009-12-02 LT LTEP16192250.5T patent/LT3135691T/lt unknown
- 2009-12-02 SI SI200931680T patent/SI2370468T1/sl unknown
- 2009-12-05 SA SA112331005A patent/SA112331005B1/ar unknown
- 2009-12-05 SA SA109300720A patent/SA109300720B1/ar unknown
2011
- 2011-05-03 TN TN2011000216A patent/TN2011000216A1/fr unknown
- 2011-05-30 MX MX2015000383A patent/MX341014B/es unknown
- 2011-05-31 IL IL213273A patent/IL213273A0/en active IP Right Grant
- 2011-06-01 CL CL2011001296A patent/CL2011001296A1/es unknown
- 2011-06-10 MA MA33933A patent/MA32892B1/fr unknown
- 2011-06-13 CR CR20110324A patent/CR20110324A/es unknown
- 2011-06-13 EC EC2011011127A patent/ECSP11011127A/es unknown
- 2011-06-14 CO CO11073992A patent/CO6382139A2/es active IP Right Grant
- 2011-07-13 ZA ZA2011/05164A patent/ZA201105164B/en unknown
2012
- 2012-09-14 US US13/619,920 patent/US8765128B2/en active Active
- 2012-09-14 US US13/619,730 patent/US8747850B2/en active Active
- 2012-09-14 US US13/619,910 patent/US8729249B2/en active Active
2014
- 2014-01-24 CL CL2014000181A patent/CL2014000181A1/es unknown
- 2014-03-13 IL IL231525A patent/IL231525B/en active IP Right Grant
2015
- 2015-07-03 PH PH12015501515A patent/PH12015501515A1/en unknown
- 2015-12-15 JP JP2015244007A patent/JP6074018B2/ja active Active
2016
- 2016-02-04 AU AU2016200725A patent/AU2016200725C1/en active Active
2017
- 2017-01-05 JP JP2017000641A patent/JP6309657B2/ja active Active
- 2017-06-09 AU AU2017203929A patent/AU2017203929B2/en active Active
- 2017-07-03 CY CY20171100707T patent/CY1119172T1/el unknown
2018
- 2018-11-09 HR HRP20181868TT patent/HRP20181868T1/hr unknown
- 2018-11-09 CY CY181101191T patent/CY1121025T1/el unknown

Also Published As

Publication number	Publication date
CA2743433A1 (en)	2010-06-24
ES2697098T3 (es)	2019-01-22
DK3135691T3 (en)	2018-11-19
MX2011005677A (es)	2011-06-30
JP2012510280A (ja)	2012-05-10
LT3135691T (lt)	2018-11-12
GEP20146207B (en)	2014-12-10
SA112331005B1 (ar)	2015-09-13
JP6074018B2 (ja)	2017-02-01
SI3135691T1 (sl)	2018-12-31
PL2370468T3 (pl)	2017-09-29
HUE051288T2 (hu)	2021-03-01
RU2560257C2 (ru)	2015-08-20
JP5863458B2 (ja)	2016-02-16
PH12015501515A1 (en)	2015-12-14
TWI523866B (zh)	2016-03-01
RU2011124751A (ru)	2013-01-10
CR20110324A (es)	2011-07-28
AU2016200725A1 (en)	2016-02-25
CY1121025T1 (el)	2019-12-11
CL2014000181A1 (es)	2014-07-25
TW201446805A (zh)	2014-12-16
HUE035047T2 (en)	2018-05-02
ZA201105164B (en)	2012-03-28
HRP20171011T8 (hr)	2019-01-25
IL213273A0 (en)	2011-07-31
AU2017203929B2 (en)	2019-03-28
CL2011001296A1 (es)	2011-08-26
JP2016117721A (ja)	2016-06-30
US20130109844A1 (en)	2013-05-02
EP2370468A1 (en)	2011-10-05
HK1190414A1 (zh)	2014-07-04
AU2009328318A1 (en)	2011-07-28
WO2010069765A1 (en)	2010-06-24
SI3431502T1 (sl)	2021-01-29
AU2016200725B2 (en)	2017-05-25
KR101838299B1 (ko)	2018-03-14
MY185200A (en)	2021-04-30
KR20110097839A (ko)	2011-08-31
PT3135691T (pt)	2018-11-27
EP3431502A1 (en)	2019-01-23
ES2827277T3 (es)	2021-05-20
US20130109841A1 (en)	2013-05-02
AU2009328318B2 (en)	2015-11-05
MX341014B (es)	2016-08-03
NZ593853A (en)	2013-03-28
US8765128B2 (en)	2014-07-01
AU2016200725C1 (en)	2017-10-19
HRP20181868T1 (hr)	2019-01-11
IL231525B (en)	2019-07-31
SG187518A1 (en)	2013-02-28
RU2015127471A (ru)	2018-12-21
PT3431502T (pt)	2020-10-29
SG171851A1 (en)	2011-07-28
PL3431502T3 (pl)	2020-12-28
PE20120343A1 (es)	2012-04-16
US8741290B2 (en)	2014-06-03
AR074439A1 (es)	2011-01-19
CO6382139A2 (es)	2012-02-15
US20130109840A1 (en)	2013-05-02
EP3135691B1 (en)	2018-08-15
AU2017203929A1 (en)	2017-07-06
CN103351438B (zh)	2016-04-20
EP3431502B1 (en)	2020-07-22
MA32892B1 (fr)	2011-12-01
SA109300720B1 (ar)	2013-05-25
TW201023892A (en)	2010-07-01
US8729249B2 (en)	2014-05-20
RS56204B1 (sr)	2017-11-30
TWI459964B (zh)	2014-11-11
GEP20135930B (en)	2013-10-10
ECSP11011127A (es)	2011-07-29
TN2011000216A1 (en)	2012-12-17
BR122019023930B1 (pt)	2021-05-04
US20110239316A1 (en)	2011-09-29
BRPI0923231B1 (pt)	2020-04-28
DK2370468T3 (en)	2017-06-19
RS58018B1 (sr)	2019-02-28
EP3135691A1 (en)	2017-03-01
CA2743433C (en)	2019-06-11
EP2370468B1 (en)	2017-04-05
ES2629855T3 (es)	2017-08-16
SI2370468T1 (sl)	2017-08-31
CN102227446B (zh)	2015-10-21
US8747850B2 (en)	2014-06-10
CY1119172T1 (el)	2018-02-14
CN102227446A (zh)	2011-10-26
HUE040553T2 (hu)	2019-03-28
HRP20171011T1 (hr)	2017-09-22
CN103351438A (zh)	2013-10-16
JP6309657B2 (ja)	2018-04-11
PT2370468T (pt)	2017-07-13
IL231525A0 (en)	2014-04-30
LT2370468T (lt)	2017-07-10
AU2009328318C1 (en)	2017-11-02
HK1162536A1 (zh)	2012-08-31
BRPI0923231B8 (pt)	2021-05-25
JP2017099392A (ja)	2017-06-08
EP3757132A1 (en)	2020-12-30
PL3135691T3 (pl)	2019-02-28
MY192567A (en)	2022-08-29

Publication	Publication Date	Title
BRPI0923231A2 (pt)	2016-01-26	anticorpo anti-cmet.
BRPI0807991A2 (pt)	2014-06-17	Anticorpos anti-il-23r elaborados.
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
NO2021006I1 (no)	2021-02-15	Quofenix, delafloksacin
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
DK3072906T3 (da)	2021-12-13	Antistofformulering
EP2358392A4 (en)	2012-08-29	ANTIBODY FORMULATION
BRPI0912260A2 (pt)	2015-10-06	tonalizador.
BRPI0918430A2 (pt)	2015-11-24	4-fenil-1h-pirazóis inseticidas.
DK2651436T3 (da)	2016-06-20	Mycobakterie antigen sammensætning.
EP2337798A4 (en)	2012-10-24	SPECIFIC ANTIBODIES OF THE ASB
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
BRPI0817427A2 (pt)	2015-06-16	Anticorpo anti-bst2
IT1396406B1 (it)	2012-11-19	Stantuffo.
BRPI0912716A2 (pt)	2015-10-13	composto.
BRPI0912769A2 (pt)	2015-10-13	anticorpos anti-pirb
IT1391534B1 (it)	2012-01-11	Barriera.
FR2932857B1 (fr)	2010-08-13	Agrafe.
IT1396642B1 (it)	2012-12-14	Statore.
FI7604U1 (fi)	2007-08-09	Tuntoelin
ITME20080002A1 (it)	2009-09-08	Filcomplex - potabilizzatore di acque.
BRPI0909137A2 (pt)	2015-08-04	Embreagem.
NL1037357C2 (nl)	2010-04-09	Klimatisatie-inrichting.
FR2935319B1 (fr)	2011-05-20	Fourgonnette amenagee.
NL1036071C (nl)	2010-04-15	Zelfperforerende ordner.

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-08-20	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-03-03	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-04-28	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/04/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF